Table of Contents Table of Contents
Previous Page  121 / 812 Next Page
Information
Show Menu
Previous Page 121 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S117

EW03

Predictors for readmission within one

year after discharge from an alcohol

rehabilitation program

M. Müller

, G. Weniger , S. Prinz , S. Vetter , S. Egger

University Hospital for Psychiatry Zurich, ZIP-Rheinau, Zurich,

Switzerland

Corresponding author.

Introduction

Alcohol use disorders have been associated with an

increased risk of frequent readmissions. This study aimed to exam-

ine factors that contribute to the risk for readmission within one

year after discharge from an alcohol rehabilitation program.

Methods

Rehospitalization status was assessed for all patients

with an alcohol use disorder as primary diagnosis (

n

= 468) admit-

ted to our inpatient unit between July 1, 2012, and June 30, 2014.

All patients were followed up for one year after their first hos-

pitalization (index hospitalization) within this period. Time to

readmission within one year after discharge was measured using

the Kaplan–Meiermethod. Risk factors for readmissionwere exam-

ined using Cox proportional hazard regression models. Three set of

variables were selected to be included in the analyses:

– demographic features at time of admission of index hospitaliza-

tion;

– comorbid conditions at time of admission of index hospitaliza-

tion;

– treatment-related variables in relation to the index hospitaliza-

tion including observer-rated outcome measures.

Results

Readmissions within one year after discharge from an

alcohol rehabilitation program as well as the corresponding time

to readmission were linked to higher numbers of previous hospi-

talizations and the presence of comorbid opioid use disorders.

Conclusion

Higher numbers of past treatments for AUD are indi-

cators for a chronic course of the disorder, which, in turn, increase

the risk of further relapses. Our findings further confirmed previous

findings suggesting high rates of comorbidity among alcohol and

opioid use disorders, and their link with poorer clinical outcomes.

Keywords

Alcohol use disorder; Alcohol rehabilitation

program; Readmission; Survival analysis

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.121

EW04

Interactions between mephedrone

and alcohol in humans:

Cardiovascular and subjective effects

M. Farré

1 ,

, C. Perez-Ma˜na

2

, E. de Souza

3

, J. Mateus

2

,

E. Theunisen

3

, K. Kuypers

3

, J. Ramaekers

3

, F. Fonseca

4

,

M. Torrens

4

, E. Olesti

2

, R. de la Torre

2

, E. Papaseit

2

1

Hospital Universitari Germans Trias i Pujol-IGTP-IMIM-UAB,

Clinical Phamacology, Badalona, Spain

2

Hospital del Mar Medical Research Institute-IMIM-UAB and UPF,

Human Pharmacology, Badalona, Spain

3

Faculty of Psychology and Neuroscience, Maastricht University,

Neuropsychology and Psychopharmacology, Maastricht, Netherlands

4

Institut de Neuropsiquiatria i Addiccions, Parc de Salut

Mar-IMIM-UAB, Addiction Unit, Badalona, Spain

Corresponding author.

Introduction

Mephedrone is a synthetic cathinone deriva-

tive included in the class of “New-Novel Psychoactive Sub-

stances”. Synthetic cathinones are marketed as “bath salts” or

“plant food” and gained notable popularity for similar effects

to 4-methylenedioxymethamphetamine (MDMA, ecstasy), or

amphetamines. Mephedrone is commonly consumed simulta-

neously with alcohol.

Objectives and aims

The aim of the present study was to evaluate

the interactions between mephedrone and ethanol in humans.

Methods

Twelve healthy male, recreational users of psychostim-

ulants participated as outpatients in four experimental sessions.

They received a single oral dose of mephedrone (200mg) and

alcohol (0.8 g/kg), mephedrone placebo and alcohol (0.8 g/kg),

mephedrone (200mg) and placebo alcohol, and both placebos.

Design was double-blind, double-dummy, randomized, cross-over

and controlled with placebo. Study variables included: vital signs

(blood pressure, heart rate, temperature, and pupil diameter), sub-

jective effects (visual analogue scales-VAS, ARCI-49 item short

form, and VESSPA questionnaire).

Results

The combination produced an increase in the cardiovas-

cular effects of mephedrone and induced more intense feeling of

euphoria and well-being in comparison to mephedrone and alco-

hol. Mephedrone reduced the drunkenness and sedation produced

by alcohol.

Conclusions

These results are similar to those obtained with

the combination of other psychostimulants as amphetamines and

MDMA. Abuse liability of the combination is greater that induced

by mephedrone.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

Acknowledgements

Supported by grants from Instituto de Salud

Carlos III (ISCIII, FIS-FEDER, FIS PI11/01961), ISCIII-Red de

Trastornos Adictivos (RTA RD12/0028/0009), and The European

Commission (JUST/2013/DPIP/AG/4823, EU-MADNESS project).

Clara Pérez-Ma˜ná and Esther Papaseit are Rio Hortega-Juan Rodes

fellowship (ISCIII, CM12/00085, CM13/00016, JR15/00005).

http://dx.doi.org/10.1016/j.eurpsy.2016.01.122

EW05

The synthetic cannabinoids: JWH, four

years of analysis

L. Galindo

1 ,

, M. Grifell

1

, P. Quintana

2

, A. Palma

1

, J. Tirado

3

,

M. Ventura

4

, I. Fornis

4

, M. Torrens

5

, M. Farré

6

1

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,

Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain

2

Energy Control, Asociación Bienestar y Desarrollo, Energy Control,

Parc de Salut Mar, Medina de Familia, Barcelona, Spain

3

IMIM, Adictions, Barcelona, Spain

4

Energy Control, Asociación Bienestar y Desarrollo, Energy Control,

Barcelona, Spain

5

Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, IMIM,

Universitat Autònoma de Barcelona-, Adictions, Barcelona, Spain

6

Hospital Universitari Germans Trías i Pujol, IGTP, Universitat

Autònoma de Barcelona, Pharmacology, Barcelona, Spain

Corresponding author.

Introduction

Since 2004, herbal mixtures for smoking use have

been sold under the generic brand “Spice”. Many of them contain

synthetic cannabinoids (agonists of the cannabinoid receptors).

JWH-018 was one of the first spice drugs. There is no scientific evi-

dence of their effects on humans, except cases of intoxications and

users opinions.

Objective

The present study describes the presence of the syn-

thetic cannabinoids JWH’s and their characteristics in the samples

delivered for analysis to the harm reduction NGO Energy Control

from 2010 to 2014 in Spain.

Methods

From15,814 samples analyzed from2010 to 2014, those

containing synthetic cannabinoids JWH’s were studied (

n

= 47).

Analysis was done by gas chromatography–mass spectrometry.

Results

From these 47 samples containing JWH, 55% were deliv-

ered as “legal highs” (

n

= 21) and 44% as JWH. Most common

presentations were powder 47% and herbals 32%. Samples con-

taining JWH 45%(

n

= 21) were mixed with more than one kind of

JWH or were adulterated and other active principles were found

28% (

n

= 13) JWH-018, 11% (

n

= 5) JWH-210, 8% (

n

= 4) JWH-081 and